Detection of anti-SARS-CoV-2 S1 RBD-specific antibodies prior to and during the pandemic in 2011-2021 and Covid-19 observational study in 2019-2021

Nadezhda Gumanova (gumanova@mail.ru)
Institute of Preventive Medicine

Alexander U. Gorshkov
Institute of Preventive Medicine

Natalya L. Bogdanova
Institute of Preventive Medicine

Andrew I. Korolev
Institute of Preventive Medicine

Research Article

Keywords: Covid-19, vaccination, seroprevalence, collective immunity

Posted Date: February 1st, 2022

DOI: https://doi.org/10.21203/rs.3.rs-1308920/v1

License: This work is licensed under a Creative Commons Attribution 4.0 International License.
Read Full License
Abstract

Background

Longitudinal surveys to continually monitor the seroprevalence around the globe are required to support the prevention and control efforts for assessment of the levels of endemic stability in certain countries and regions. We investigated seroprevalence of anti-SARS-CoV-2-S1 receptor-binding domain (RBD)-specific antibodies in the samples of participants recruited for various cardiovascular studies unrelated to exposure to the virus in 2011-2021. A cohort study recruited in 2019-2021 was used to evaluate the vaccination and anti-IgG-SARS-CoV-2–S1 RBD-positive statuses to assess the resistance and severity of Covid-19.

Materials and Methods

The present observational study included subjects 18 years of age and older randomly selected from various cohorts previously recruited from 2011 to 2021 from the city of Moscow and Moscow Region for a total of 565 serum samples including recent participants (N = 310); recruited in 2019-2021. The phone survey of the participants of this cohort was conducted in October, 2021. Anti-SARS-CoV-2 S1 RBD-specific antibodies were assayed in the serum samples (N = 565). At endpoint (October 30, 2021), participants of the 2019-2021 cohort (N = 310) were interviewed over phone using a questionnaire that included 5 questions as follows: 1) did the participant experience a respiratory disorder at any time before or after the enrolment in the study; 2) the date of the disorder; 3) severity of the disorder, including asymptomatic, mild, medium (fever and cough), or severe (hospitalization); 4) was the participant vaccinated and the date of vaccination; and 5) brand of a vaccine.

Results

The data of the present study indicated that a small percentage (3-6%) of SARS-CoV-2-S1 RBD-specific antibodies was detected in participants recruited in 2011-2019. The percentage of SARS-CoV-2-S1 RBD-specific antibodies was increased to 16.5% in 2020 and to 46% in 2021. The vaccination rate of 238 respondents of this cohort was 58% from August, 2020 to October, 2021. If this rate is added to the rate of not vaccinated SARS-CoV-2-S1 RBD-positive subjects (11%), collective immunity was able to reach 69%. The data indicated that 12% of respondents were hospitalized. No cases of hospitalization were reported in vaccinated respondents. The morbidity rate in the subgroup of anti-SARS-CoV-2-S1 RBD-positive respondents was 5.4-fold higher than that in the subgroup of vaccinated respondents (OR = 5.4; CI: 1.4 -19.8; P = 0.01).

Conclusion

Detected small percentage of SARS-CoV-2-S1 RBD-specific antibodies in participants recruited in 2011-2019 indicated possible spreading of coronaviruses during the pre-pandemic period. Collective immunity in Moscow and Moscow region was able to reach 69% from August, 2020 to October, 2021. Obtained results demonstrated that vaccination protects against COVID-19 and related hospitalization.
Introduction

Over the past 20 years, world-wide aggressive coronavirus infections have been noted at least twice. In 2002-2003, 26 countries were affected by the SARS-CoV (severe acute respiratory syndrome coronavirus) epidemic, with a main peak in February, 2003 and a lethality rate of 10% [1]. In 2012-2013, 27 countries were attacked by MERS-CoV (Middle East respiratory syndrome coronavirus), with a lethality rate of up to 35% [2, 3, 4]. However, violent global pandemic invasion of the coronavirus disease in 2019 (Covid-19 caused by SARS-CoV-2) was the most devastating. On December 31, 2019, the Chinese Center for Disease Control reported severe cases of pneumonia of unknown etiology in Wuhan. Subsequent identification determined that the causative agent is a novel Beta coronavirus (SARS-CoV-2). The robust data on the onset of SARS-CoV-2 infection and spreading of the virus in the pre-pandemic period are unavailable [5].

Profound impact of the COVID-19 pandemic indicates the need for additional investigations into multiple aspects of coronaviruses. Longitudinal surveys to continually monitor the seroprevalence around the globe are required to support the prevention and control efforts for assessment of the levels of endemic stability in certain countries and regions.

We investigated seroprevalence of anti-SARS-CoV-2-S1 receptor-binding domain (RBD)–specific antibodies in the samples of participants recruited for various cardiovascular studies in 2011-2018. A microcirculation cohort study recruited in 2019-2021 was used to evaluate the vaccination and anti-IgG-SARS-CoV-2–S1 RBD-positive statuses to assess the resistance and severity of Covid-19. The study on microcirculation was planned before the pandemic. Thus, exposure to the virus was apparently random and unrelated to the recruitment strategy.

Materials And Method

Participants

The present observational study included subjects 18 years of age and older randomly selected from various cohorts previously recruited from 2011 to 2021 from the city of Moscow and Moscow Region at the National Research Center for Preventive Medicine, Ministry of Health Care of Russian Federation, Moscow, Russia. All subjects were involved in various cardiovascular studies, and their recruitment was unrelated to occurrence of viral infection. The groups were selected from the corresponding cohorts (Fig. 1) for a total of 565 serum samples. Recent participants (N = 310; recruited in 2019 (N = 80), 2020 (N=132), and 2021 (N = 98)) were a part of a cohort for investigation of microcirculation (from August, 2019 to August, 2021). The phone survey of the participants of this cohort was conducted in October, 2021. The primary protocol for the 2019-2021 cohort was not aimed to investigate Covid-19, indicating that the participants were exposed to Covid-19 randomly. The groups recruited from 2011 to 2018 (N = 255) included 2011 (N = 30), 2012 (N=31), 2013 (N = 22), 2014 (N = 45), 2015 (N = 45), 2016 (N = 20),
2017 (N = 27), and 2018 (N = 35). At the time of the recruitment visit, evaluation of the participants of the 2019-2021 cohort included assessment of baseline cardiovascular characteristics.

Anti-SARS-CoV-2 S1 RBD-specific antibodies were assayed in the serum samples (N = 565). At endpoint (October 30, 2021), participants of the 2019-2021 cohort (N = 310) were interviewed over phone using a questionnaire that included 5 questions as follows: 1) did the participant experience a respiratory disorder at any time before or after the enrolment in the study; 2) the date of the disorder; 3) severity of the disorder, including asymptomatic, mild, medium (fever and cough), or severe (hospitalization); 4) was the participant vaccinated and the date of vaccination; and 5) brand of a vaccine.

The following exclusion criteria were used: any acute inflammation, including oral or dental; hematological diseases; left ventricular ejection fraction below 40%; diabetes mellitus; chronic kidney or liver failure; oncological diseases; mental illness; autoimmune diseases; any type of blood sugar-lowering therapy; any type of cholesterol-lowering therapy; pregnancy; and lactation. Patients with ischemic heart disease with an acute cardiovascular event less than 6 months before the enrollment were also excluded. The protocols of the study were approved by the local ethics committee and were compliant with the guidelines of the Helsinki Declaration and WHO. All participants gave their written informed consent for participation in the study with access to their personal data.

**Antibody assays**

Blood was sampled from the ulnar vein after 12-14 hours of fasting. The serum was aliquoted and stored at −76°C.

Enzyme immunoassay for qualitative detection of IgG antibodies against SARS-CoV-2 S1 RBD was performed using an anti-SARS-CoV-2 ELISA E111-IVD kit (Mediagnost, Germany) by two-step enzyme-linked immunosorbent assay with recombinant SARS-CoV-2-S1 receptor binding domain (RBD) according to the manufacturer's instructions. The samples were considered antibody-positive at > 5-fold cut-off value or if the signal was higher than the optical density of 0.830. The samples with < 3-fold cut-off value or with the signals lower than the optical density of 0.498 were considered antibody-negative. Samples from 3-fold to 5-fold cut-off or with the intermediate optical density values were considered borderline positive. The cut-off values were selected to ensure the exclusion of false positive results with a high probability. The assay was characterized by 95.55% sensitivity, 98.36% specificity, and 10.6% inter-assay variance.

The use of S1-RBD protein as an antigen in the assay enhances analytical specificity because the S1-RBD proteins of other human pathogenic coronaviruses share only 62%-74% identity with SARS-CoV-2 [6]. However, cross-reactivity cannot be completely excluded due to relatively high similarity of the S1-RBD proteins of SARS-CoV-2 and SARS-CoV. Cross-reactivity of antibodies not specific to SARS-CoV-2 against SARS-CoV-2-S1 RBD protein in anti-SARS-CoV-2 ELISA E111-IVD was examined using the sera containing known antibodies against previously confirmed infections with other viruses. According to the data provided by the manufacturer, the ELISA kits did not cross-react with antibody-positive sera against Beta
Corona HKU1, Beta Corona OC43, Alpha Corona 229E, and Alpha Corona NL63 confirmed by polymerase chain reaction tests and against SARS-CoV, varicella-zoster virus, hepatitis A, B, and C viruses, Epstein-Barr virus, cytomegalovirus, and herpes simplex virus.

Comparison with alternative commercially available assays indicates that the Mediagnost E111-IVD kits are well suited for the detection of anti-SARS-CoV-2 IgG antibodies. The S1 RBD viral antigen used as the binding target for antibodies is apparently superior to complete spike S1 protein or nucleocapsid protein, which both generate higher rates of false-positive results according to the data of the competitor assays [7].

**Statistical analysis**

Statistical analysis was done using SPSS IBM version 23 software. P values below 0.05 were considered significant. Significance of Kaplan-Meier analysis was estimated with Log rank Mantel-Cox test.

**Results**

We investigated the presence of anti-SARS-CoV-2-S1 RBD–specific antibodies in the serum samples of 565 individuals enrolled in various cardiovascular studies from 2011 to 2021. All participants from 24 to 86 years of age (mean ± SD: 54 ± 9.2 years) were randomly selected from the three cohorts from 2011 to 2018 enrolled for various cardiovascular studies. A single cohort was recruited in 2019-2021 for a microcirculation study, which was not aimed to investigate viral infections. Thus, any contact with the viruses was apparently random for all participants. Moreover, exclusion criteria included acute systemic inflammation and oral or dental inflammation.

IgG antibodies against SARS-CoV-2-S1 RBD protein in the serum were assayed in 565 participants of all groups recruited from 2011 to 2021 (Table 1, Fig. 2). The signals corresponding to IgG antibodies against SARS-CoV-2-S1 RBD were detected in 1 out of 30 participants in 2011, 2 out of 31 participants in 2012, 1 out of 22 participants in 2013, 3 out of 45 participants in 2014, 2 out of 45 participants in 2015, 1 out of 20 participants in 2016, 0 out of 27 participants in 2017, 1 out of 35 participants in 2018, 4 out of 80 participants in August-December, 2019, 22 out of 132 participants in 2020, and 45 out of 98 participants enrolled from December, 2020 to August, 2021 (Table 1, Fig. 2). The data indicated that IgG-positive samples with anti-SARS-CoV-2-S1 RBD antibodies were present in 3-6% of participants enrolled from 2011 to 2019. The fraction of IgG-positive participants was increased to 16.5% in 2020 and to 46% in 2021. The cohort enrolled in 2019-2021 was analyzed based on months. The number of participants and percentage of IgG-positive samples in the groups are presented in Table 2. The distribution of IgG-positive samples in 2019-2021 demonstrated that the fraction of anti-SARS-CoV-2-S1 RBD-positive samples was increased from April, 2021 to August, 2021 compared to that in January–March, 2021. The fraction of SARS-CoV-2-S1 RBD-positive samples was increased up to 75% in August, 2021, when enrolment in this cohort has ended (Table 2, Fig. 3).
Table 1
Participants analyzed based on years from 2011 to 2021 and serum anti-SARS-CoV-2 IgG antibody status.

| Year-based groups | Total N and age (mean±SD) | Year | N for indicated years | Serum anti-SARS-CoV-2 (S1-RBD) IgG antibody-positive (N; %) |
|-------------------|---------------------------|------|-----------------------|----------------------------------------------------------|
| 2011-2013         | 83; 61.2±9.4              | 2011 | 30                    | 1 (3.3)                                                  |
|                   |                           | 2012 | 31                    | 2 (6.5)                                                  |
|                   |                           | 2013 | 22                    | 1 (4.5)                                                  |
| 2014-2015         | 90; 53.6±7.4              | 2014 | 45                    | 3 (6.7)                                                  |
|                   |                           | 2015 | 45                    | 2 (4.4)                                                  |
| 2016-2018         | 82; 58.1±11.1             | 2016 | 20                    | 1 (5.0)                                                  |
|                   |                           | 2017 | 27                    | 0 (0.0)                                                  |
|                   |                           | 2018 | 35                    | 1 (2.9)                                                  |
| 2019-2021         | 310; 42±8.7               | 2019 (from August to December) | 80                | 4 (5.0)                                                  |
|                   |                           | 2020 | 132                   | 22 (16.5)                                                |
|                   |                           | 2021 (from December, 2020 to August, 2021) | 98              | 45 (45.9)                                                |
Table 2
Participants (N and %) with serum anti-SARS-CoV-2 (S1) IgG-positive status based on indicated months in the 2019-2021 group.

| Months                  | Participants (N) | Participants with serum anti-SARS-CoV-2 S1 IgG-positive status (%) |
|-------------------------|------------------|---------------------------------------------------------------|
| August-September, 2019  | 27               | 3.7                                                          |
| October-December, 2019  | 53               | 5.7                                                          |
| January-February, 2020  | 32               | 6.3                                                          |
| March-May, 2020         | 11               | 27.3                                                         |
| June-July, 2020         | 41               | 19.5                                                         |
| August-September, 2020  | 30               | 16.7                                                         |
| October-December, 2020  | 19               | 15.8                                                         |
| January-February, 2021  | 8                | 25.0                                                         |
| March, 2021             | 25               | 8.0                                                          |
| April, 2021             | 22               | 54.5                                                         |
| May, 2021               | 11               | 72.7                                                         |
| June, 2021              | 14               | 64.3                                                         |
| July, 2021              | 13               | 61.5                                                         |
| August, 2021            | 3                | 75                                                           |

Anti-SARS-CoV-2-S1 RBD-specific antibodies were detected in 70 (22.5%) participants of the cohort enrolled in 2019-2021 (N = 310) (Table 3). Subgroups of participants with anti-SARS-CoV-2-S1 RBD-positive and -negative statuses had similar clinical, demographic, and biochemical parameters, including sex, age, systolic blood pressure, diastolic blood pressure, body mass index, waist circumference, lipid profile, fibrinogen, blood glucose, and C-reactive protein levels (data not shown). The participants of the 2019-2021 cohort were subsequently followed up by phone survey starting from October 30, 2021. Overall, 251 out of enrolled 310 (81%) participants were possible to follow up by phone survey with 13 participants (4.2%) refused to answer. Those participants who were able to answer the questions of the survey were designated respondents, including 93 out of 238 (39%) respondents who reported any symptoms of respiratory disorders. These symptoms were classified into mild (47%), medium (cough,
cold, and fever) (41%), and severe (hospitalization) (12%) cases. Covid-19 was verified by PCR-test in 91% of 93 participants who reported any symptoms (Table 3).
Table 3
Covid-19 infections in respondents enrolled in 2019-2021.

| Description of participants/respondents | Respondents/total participants or respondents (N/N; %) | IgG-positive respondents (N/N; %) | IgG-negative respondents (N/N; %) |
|-----------------------------------------|--------------------------------------------------|---------------------------------|----------------------------------|
| **Participants**                        |                                                  |                                 |                                  |
| All participants, 2019-2021             | 310 (100)                                        | 70/310 (22.5)                   | 240/310 (77.5)                   |
| Available for phone survey              | 251/310 (81)                                     |                                 |                                  |
| Agreed to answer (respondents)          | 238/310 (77)                                     | 59/310 (19)                     | 179/310 (58)                     |
| Refused to answer                       | 13/310 (4)                                       |                                 |                                  |
| Unavailable for phone survey            | 59/310 (19)                                      |                                 |                                  |
| **Respondents**                        |                                                  |                                 |                                  |
| Symptoms and severity of respiratory disorders | 238 (100)                                    |                                 |                                  |
| Any symptoms reported                   | 93/238 (39)                                      | 30/59 (37)                      | 63/179 (35)                      |
| No symptoms reported                    | 145/238 (61)                                     | 40/59 (63)                      | 105/179 (65)                     |
| Covid-19 verified by PCR                | 85/93 (91)                                       | 30/93 (32)                      | 55/93 (59)                       |
| **Severity of respiratory disorders**   |                                                  |                                 |                                  |
| Mild                                    | 44/93 (47)                                       | 15/30 (50)                      | 28/63 (44)                       |
| Medium (cough, cold, and fever)         | 38/93 (41)                                       | 12/30 (40)                      | 26/63 (41)                       |
| Severe (hospitalization)                | 11/93 (12)                                       | 3/30 (10)                       | 9/63 (14)                        |
| Vaccination status                      | 238 (100)                                        | 59 (100)                        | 179 (100)                        |
| Vaccinated (from September, 2020 to October, 2021) | 137/238 (58)                             | 33/59 (56)                      | 104/179 (58)                     |
| Not vaccinated                          | 97/238 (40)                                      | 25/59 (42)                      | 72/179 (40)                      |
| Cannot answer                           | 4/238 (2)                                        | 1/59 (2)                        | 3/179 (2)                        |
| Brand of vaccine in respondents who were able to answer | 119 (100)                                    |                                 |                                  |

*T-test, P<0.05.

**Odds ratio = 5.4 (CI: 1.4-19.8, P = 0.01) for IgG-positive respondents with reported relapse of respiratory disorders versus vaccinated respondents who reported relapse of Covid-19.
| Description of participants/respondents                                                                 | Respondents/total participants or respondents (N/N; %) | IgG-positive respondents (N/N; %) | IgG-negative respondents (N/N; %) |
|--------------------------------------------------------------------------------------------------------|--------------------------------------------------------|----------------------------------|----------------------------------|
| Gam-COVID-Vac (Sputnik V)                                                                            | 103/119 (87)                                           |                                  |                                  |
| Other vaccines:                                                                                       | 16/119 (13)                                            |                                  |                                  |
| CoviVac                                                                                               | 7/119 (6)                                              |                                  |                                  |
| EpiVacCorona                                                                                          | 5/119 (4)                                              |                                  |                                  |
| Sputnik Lite                                                                                          | 4/119 (3)                                              |                                  |                                  |
| Vaccinated before enrolment, IgG-status (Gam-COVID-Vac, N=13; CoviVac, N=1)                           | 14/238 (6)                                             | 9/14 (64)                        | 5/14 (36)                        |
| Days from vaccination to the enrollment visit                                                          | 9-151                                                  | 117-169*                         |                                  |
| Covid-19 disease status                                                                               | 238 (100)                                              | 59 (100)                         | 179 (100)                        |
| Covid-19 verified with PCR-tests                                                                     | 94/238 (40)                                            | 27/59 (46)                       | 66/179 (37)                      |
| Not verified                                                                                          | 144/238 (60)                                           | 31/59 (54)                       | 113/179 (63)                     |
| IgG-positive respondents who were able to recall the date of respiratory disorders                     | 59 (100)                                               |                                  |                                  |
| Reported a relapse of respiratory disorders after the enrollment visit during 10-629 days of follow-up | 12/59 (20)*                                            |                                  |                                  |
| Reported a respiratory disorder before the enrollment visit during 27-476 of days follow-up           | 21/59 (36)                                             |                                  |                                  |
| Covid-19 verified by PCR-tests                                                                       | 16/21 (76)                                             |                                  |                                  |
| No respiratory disorders reported                                                                     | 26/59 (44)                                             |                                  |                                  |
| Asymptomatic                                                                                          | 2/21 (10)                                              |                                  |                                  |
| Mild                                                                                                  | 10/21 (48)                                             |                                  |                                  |
| Medium (cough, cold, and fever)                                                                       | 8/21 (38)                                              |                                  |                                  |
| Severe (hospitalization)                                                                             | 1/21 (5)                                               |                                  |                                  |
| Severity grade of respiratory disorders after the enrollment visit in IgG-positive respondents who were able to answer | 12 (100)                                               |                                  |                                  |

*T-test, P<0.05.

**Odds ratio = 5.4 (CI: 1.4-19.8, P = 0.01) for IgG-positive respondents with reported relapse of respiratory disorders versus vaccinated respondents who reported relapse of Covid-19.
| Description of participants/respondents | Respondents/total participants or respondents (N/N; %) | IgG-positive respondents (N/N; %) | IgG-negative respondents (N/N; %) |
|-----------------------------------------|-------------------------------------------------------|----------------------------------|----------------------------------|
| Covid-19 verified by PCR-tests          | 12/12 (100)                                           |                                  |                                  |
| Asymptomatic                            | 1/12(8)                                               |                                  |                                  |
| Mild                                    | 6/12 (50)                                              |                                  |                                  |
| Medium (cough, cold, and fever)         | 4/12 (33)                                              |                                  |                                  |
| Severe (hospitalization)                | 1/12 (8)                                               |                                  |                                  |
| All vaccinated respondents              | 137 (100)                                             |                                  |                                  |
| Vaccinated respondents who were able to recall the date of respiratory disorders | 118/137 (86)                                         |                                  |                                  |
| Respondents with reported respiratory disorders before vaccination | 39/118 (33)                                         |                                  |                                  |
| Respondents with reported relapse of Covid-19 in vaccinated subjects verified by PCR-tests (from 92 to 183 days after the vaccination; mean 152 days) | **3/79 (4)**                                           | 1/3 (33.3)                        | 2/3 (66.7)                       |
| Severity grade of relapse respiratory disorders in vaccinated respondents |                                  |                                  |                                  |
| Mild                                    | 2/79 (3)                                               |                                  |                                  |
| Medium (cough, cold, and fever)         | 1/79 (1)                                               |                                  |                                  |
| Severe (hospitalization)                | -                                                      |                                  |                                  |

*T-test, P<0.05.

**Odds ratio = 5.4 (CI: 1.4-19.8, P = 0.01) for IgG-positive respondents with reported relapse of respiratory disorders versus vaccinated respondents who reported relapse of Covid-19.

According to the data of the follow up survey, 137 (58%) out of 238 respondents were vaccinated from September, 2020 to October, 2021, including 87% of respondents, which were able to recall the information, were vaccinated with Gam-COVID-VAC (Sputnik V) (N = 119) (Table 3). A total of 14 respondents of the 2019-2021 cohort were vaccinated before the enrolment, and anti-SARS-CoV-2-S1 RBD–specific antibodies were detected in 64% of these 14 individuals. Thus, 9 out of 70 IgG-positive respondents of the 2019-2021 cohort could have developed specific IgG antibodies due to vaccination, and the remaining 61 out of 310 (20%) of IgG-positive respondents could have developed IgG antibodies due to Covid-19. Notably, time intervals between vaccination and recruitment visit in these two subgroups were significantly different; the corresponding values were 9-151 days for anti-IgG-SARS-CoV-2-S1 RBD–
positive respondents and 117-169 days for anti-IgG-SARS-CoV-2-S1 RBD-negative respondents (P < 0.05) (Table 3). The differences in seropositivity of these subgroups can be due to the duration of immunity, which is estimated to be 3-4 months, or due to efficacy of the vaccine.

All respondents (N=238) were divided into four partly overlapping subgroups, including vaccinated (subgroup A, N = 137), anti-SARS-CoV-2-S1 RBD-positive (subgroup B, N = 59), not vaccinated (subgroup C, N = 97), and anti-SARS-CoV-2-S1 RBD-negative (subgroup D, N = 179). The Kaplan-Meier analysis was performed after a maximum of 2.5-year follow-up period to determine the differences in the relapse of Covid-19 between these subgroups (Table 4, Fig. 3). The Kaplan-Meier curves based on the relapse outcome are shown in Fig. 3, indicating that the vaccinated subgroup was less likely to get sick with Covid-19 compared to the subgroups B, C, and D according to the Log rank test (p = 0.001; Table 4). Unexpectedly, the subgroup B of anti-SARS-CoV-2-S1 RBD-positive respondents had no Covid-19 resistance compared with that of the anti-SARS-CoV-2-S1 RBD-negative (D) and not vaccinated (C) subgroups (p > 0.05; Log rank test). The data indicated that 20% of anti-SARS-CoV-2-S1 RBD-positive and 4% of vaccinated respondents had a relapse of Covid-19 within 10-629 days after the recruitment visit date and 92-183 days after vaccination, respectively. The morbidity rate in the subgroup of anti-SARS-CoV-2-S1 RBD-positive respondents was 5.4-fold higher than that in the subgroup of vaccinated respondents (OR = 5.4; CI: 1.4 -19.8; P = 0.01; Table 3). Notably, the subgroup of anti-SARS-CoV-2-S1 RBD-negative respondents was less likely to get sick with Covid-19 compared to the subgroup of not vaccinated (p = 0.001; Log rank test). Apparently, the respondents who were not sick with Covid-19 had stronger overall immunity. However, IgG-positive and -negative participants of the 2019-2021 cohort had similar levels of various biochemical parameters, including C-reactive protein, and anthropometric and clinical parameters (data not shown).

Table 4
Pairwise comparisons of the groups of respondents with various vaccination and IgG statuses according to Kaplan-Meier analysis (Log rank Mantel-Cox test).

| Groups          | Vaccinated | IgG-positive | Not vaccinated | IgG-negative |
|-----------------|------------|--------------|----------------|--------------|
|                 | Chi squared test | P | Chi squared test | P | Chi squared test | P | Chi squared test | P |
| Vaccinated      | 20.75       | 0.001        | 51.20          | 0.001        | 20.93          | 0.001 |
| IgG-positive    | 20.75       | 0.001        | 1.59           | 0.21         | 1.31           | 0.25  |
| Not vaccinated  | 51.20       | 0.001        | 1.59           | 0.21         | 19.74          | 0.001 |
| IgG-negative    | 20.93       | 0.001        | 1.30           | 0.25         | 19.73          | 0.001 |
Thus, the data of the present study indicated that a small percentage (3-6%) of SARS-CoV-2-S1 RBD-specific antibodies was detected in participants recruited in 2011-2019. The percentage of SARS-CoV-2-S1 RBD-specific antibodies was increased to 16.5% in 2020 and to 46% in 2021. The vaccination rate of 238 respondents of this cohort was 58% from August, 2020 to October, 2021. If this rate is added to the rate of not vaccinated SARS-CoV-2-S1 RBD-positive subjects (11%; 25/238), collective immunity was able to reach 69%.

The data indicated that 12% of respondents who reported any symptoms of respiratory disorders (N=93) were hospitalized. No cases of hospitalization were reported in vaccinated respondents. No deaths were reported in respondents who participated in the follow up phone survey.

**Discussion**

Questions related to the origin of coronavirus remain on scientific agenda. Hence, the actual time frame of the onset of severe acute respiratory syndrome due to SARS-CoV-2 infection and possible spreading of coronaviruses during the pre-pandemic period are of great interest. SARS-CoV-2 seroprevalence had considerable geographic variability, as expected in the case of a pandemic [8]. In addition, anti-SARS-CoV-2 RBD-specific antibodies were detected in Italy several months before the first Covid-19 patient was identified. These findings have a potential to redefine the timeframe for the onset of Covid-19 pandemic with detection anti-SARS-CoV-2 RBD-specific antibodies in 11.6% of participants recruited from September 2019 to August 2021 [9].

The results of an internet search carried out in Italy using Google Trends (Google Inc., Mountain View, CA) with most commonly reported COVID-19 symptoms in Italy indirectly supports the conclusions of Apolone et al. [9] that SARS-CoV-2 may have started to circulate in Italy in September 2019, specifically in Lombardy, before the declared pandemic period [10].

The results from multiple independent assays support these observations, demonstrating the presence of preexisting antibodies, which were able to recognize SARS-CoV-2, in uninfected individuals [11–13]. These findings corresponded with the results of the present study on the presence of anti-SARS-CoV-2-S1 RBD-specific antibodies in 5% of participants recruited in August-December, 2019.

Cross-reactivity between SARS-CoV-2 and other circulating coronaviruses can explain our observations. Almost 90% of the human population is seropositive for at least three known persistently circulating coronaviruses, such as HCoV-OC43 (human coronavirus OC43), HCoV-HKU1, HCoV-NL63, and HCoV-229E, which cause certain respiratory disorders [12]. A study demonstrated ELISA cross-reactivity of SARS-related coronaviruses, MERS, and SARS-CoV sera only with the full SARS-CoV-2 S protein, but not with the S1 antigen, which is in agreement with several other studies that failed to detect cross-reactivity of anti-SARS-related coronavirus antibodies with SARS-CoV-2 RBD. Cross-neutralization activity between convalescent sera from SARS and COVID-19 patients was shown to be limited [14]. Moreover, the lack of cross-reactivity between the S1 subdomain of SARS-CoV-2 and other SARS-associated coronaviruses was used to develop a target antigen for highly specific serological assays [4, 5].
Serologic surveys are valuable tools for investigation of public health; however, these surveys are able to assess the presence of an infection only indirectly and are less reliable than standard diagnostic methods. ELISAs specific for the detection of anti-SARS-CoV-2 antibodies for RBD, S1, and N proteins have sensitivities of 88.4%, 89.3%, and 72.9%, respectively, and specificity of these ELISAs is over 94% [15]. According to manufacturer characteristics, ELISA kits used in the present study provide diminished cross-reactivity with other coronaviruses (Materials and Methods).

The presence of anti-SARS-CoV-2-S1 RBD-specific antibodies in the samples in 2011-2018 can be due to long-term humoral immunity induced by previous infections of coronaviruses, including SARS-CoV or MERS-CoV. In general, IgG antibodies appear at a later stage of immune response because IgGs undergo affinity maturation through somatic mutations, resulting in high affinity against a target antigen and enhanced capacity to neutralize the pathogens [4, 5]. A long-lasting immunity (up to 6 years) against these viruses has been demonstrated previously [4, 5].

Obtained results corresponded with previous observations by León et al demonstrated that vaccination protects against COVID-19 and related hospitalization [16].

Conclusions

The present study detected anti-SARS-CoV-2-S1 RBD-specific antibodies (3-6%) in the serum of participants recruited in 2011–2019, and these findings can contribute to our understanding of the origins of SARS-CoV-2. The levels of anti-SARS-CoV-2-S1 RBD-specific antibodies were increased to 16.5% in 2020 and to 46% in 2021. From August, 2020 to October, 2021, 58% of the respondents have been vaccinated. Apparently random encounters of respondents the 2019-2020 cohort with Covid-19 can represent overall vaccination levels in general population in Moscow, Russia. Combining the number of vaccinated (58%) and unvaccinated anti-SARS-CoV-2-S1 RBD-positive subjects (11%) yielded a possible estimate for the collective immunity rate (69%). Vaccinated respondents had enhanced Covid-19 resistance, whereas anti-SARS-CoV-2-S1 RBD-positive respondents did not demonstrate any advantageous Covid-19 resistance. Disease resistance in vaccinated respondents was five-fold higher than that in the group of not vaccinated respondents, and no Covid-19-related hospitalizations were reported in vaccinated respondents. In the case of not vaccinated respondents, hospitalizations were reported in 12% of the cases associated with any symptoms of respiratory disorders. No deaths were reported in respondents. Thus, specific vaccination against SARS-CoV, but not immunity acquired via infection, provides significant protection against subsequent Covid-19.

Limitations

The main limitation of the present study is survey-based follow up in the 2019-2021 cohort. Notably, the follow up response rate in the present study was relatively high at 81%. Thus, any potential variability can be predominantly due to recall bias of the respondents, which has been reported as substantial for unrepresentative surveys [17]. However, the phone survey used as follow up in the present study was
performed by qualified study personnel, and the participants were highly likely to answer the follow up questions accurately due to potential relevance of these questions to the parental microcirculation study. Another limitation is that the dynamics of morbidity in the 2019-2021 cohort illustrated in Fig. 4 may suggest insufficient follow-up period and number of respondents, requiring additional confirmatory investigations in the future.

Declarations

Conflict of interest

The authors have no conflict of interest to declare.

References

1. Peiris JSM, Lai ST, Poon LLm, Guan Y, Yam LYC, Lim W, Nicholls J, Yee WKS, Yan WW, Cheung MT, Cheng VCC, Chan KH, Tsang DNC, Yung RWH, Ng TK, Yuen KY. SARS study group. Coronavirus as a possible cause of severe acute respiratory syndrome. The Lancet. 2003;361(9366):1319–25. [https://doi.org/10.1016/S0140-6736(03)13077-2]

2. Ramshaw RE, Letourneau ID, Hong AY, Hon J, Morgan JD, Osborne CP, Shirude S, Van Kerkhove MD, Hay SI, Pigott DM. A database of geopositioned Middle East Respiratory Syndrome Coronavirus occurrences. Sci Data. 2019;6(1):318. [https://doi.org/10.1038/s41597-019-0330-0]

3. Badawi A, Ryoo SG. Prevalence of comorbidities in the Middle East respiratory syndrome coronavirus (MERS-CoV): a systematic review and metaanalysis. Int J Infect Dis. 2016;49:129–33. [https://doi.org/10.1016/j.ijid.2016.06.015]

4. Grifoni A, Sidney J, Zhang Y, Scheuermann R, Peters B, Setteet A. A. Sequence Homology and Bioinformatic Approach. Can Predict Candidate Targets for Immune Responses to SARS-CoV-2 2020, Cell Host & Microbe 27, 671–680, 2020 Elsevier Inc. [https://doi.org/10.1016/j.chom.2020.03.002]

5. Galipeau Y, Greig M, Liu G, Driedger M, Langlois M-A. Humoral Responses and Serological Assays in SARS-CoV-2 Infections. Front Immunol. 2020;11:610688. doi:10.3389/fimmu.2020.610688.

6. Wan, et al. Serological differentiation between COVID-19 and SARS infections. Emerging Microbes Infections. 2020;9(1):1497–505. DOI:10.1080/22221751.2020.1780951.

7. Mateus J, Grifoni A, Tarke A, Sidney J, Ramirez S, Dan J, Burger Z, Rawlings S, Smith D, Phillips E, Mallal E, Lammers M, Rubiro P, Quiambao L, Sutherland A, Yu E, Antunes R, Greenbaum J, Frazier A, Markmann A, Premkumar L, Silva A, Peters B, Crotty S, Sette A, Weiskopf D. Selective and cross-reactive SARS-CoV-2 T cell epitopes in unexposed humans. Science. 2020;370:89–94. doi:10.1126/science.abd3871.
8. Rostami A, Sepidarkish M, Leeflang M, Riahi S, Shiadeh M, Esfandyari S, Mokdad H, Hotez P, Gasser R. SARS-CoV-2 seroprevalence worldwide: a systematic review and meta-analysis. Clin Microbiol Infect. 2021 Mar;27(3):331–40. doi:10.1016/j.cmi.2020.10.020.

9. Apolone G, Montomoli E, Manenti A, Boeri M, Sabia F, Hyseni I, Mazzini L, Martinuzzi D, Cantone L, Milanese G, Sestini S, Suatoni P, Marchianò A, Bollati V, Sozzi G, Pastorino U. Unexpected detection of SARS-CoV-2 antibodies in the prepandemic period in Italy. Tumori Journal 2021, Vol. 107(5) 446–451 © Fondazione IRCCS Istituto Nazionale dei Tumori 2020. https://doi.org/10.1177/0300891620974755 107(5) 446–451.

10. Lippi G, Mattiuzzi C. Unexpected volume of Google searches for COVID-19 symptoms in the prepandemic period in Lombardia, Italy. Tumori Journal 2021, Vol. 107(5) 468–469. DOI: 10.1177/0300891620980796.

11. Ng K, Faulkner N, Cornish G. Preexisting and de novo humoral immunity to SARS-CoV-2 in humans. Science. 2020;370:1339–43. doi:10.1126/science.abe1107.

12. Sette A, Crotty S. Pre-existing immunity to SARS-CoV-2: the knowns and unknowns. Nat Rev Immunol. 2020;7:1–2. <background-color:#CFBFB1;uvertical-align:super;>https://doi.org/10.1038/s41577-020-0389-z</background-color:#CFBFB1;uvertical-align:super;>.

13. Palermo A, Salvarani C, Sarti M, Boaretto G, Manni L, Mascia M. Comments on: “Unexpected detection of SARS-CoV-2 antibodies in the prepandemic period in Italy”. Tumori Journal 2021, Vol. 107(5) 470–471. <background-color:#CFBFB1;uvertical-align:super;>https://doi.org/10.1177/0300891621992430</background-color:#CFBFB1;uvertical-align:super;>.

14. Ou X, Liu Y, Lei X, Li P, Mi D, Ren L, Guo L, Guo R, Chen T, Hu J, Xiang Z, Mu Z, Chen X, Chen J, Hu K, Jin Q, Wang J, Qian Z. Characterization of spike glycoprotein of SARS-CoV-2 on virus entry and its immune cross-reactivity with SARS-CoV. Nature communications. 2020;11:1620. https://doi.org/10.1038/s41467-020-15562-9.

15. Brigger D, Horn M, Pennington LF, Powell AE, Siegrist D, Weber B, Engler O, Piezzi V, Damonti L, Iseli P, Hauser C, Froehlich TK, Villiger PM, Bachmann MF, Leib SL, Bittel P, Fiedler M, Largiadèr C, Marschall J, Stalder H, Kim PS, Jardetzky T, Eggel A, Nagler M. Accuracy of serological testing for SARS-CoV-2 antibodies: first results of a large mixed-method evaluation study Allergy;76(3):853-2021865. doi: 10.1111/ALL.14608.

16. León TM, Dorabawila V, Nelson L, et al. COVID-19 Cases and Hospitalizations by COVID-19 Vaccination Status and Previous COVID-19 Diagnosis — California and New York, May–November 2021. MMWR Morb Mortal Wkly Rep. DOI: http://dx.doi.org/10.15585/mmwr.mm7104e1external icon.

17. Bradley VC, Kuriwaki S, Isakov M, Sejdinovic D, Meng XL, Flaxman S. Unrepresentative big surveys significantly overestimated US vaccine uptake. Nature. 2021;600:695–700. doi:10.1038/s41586-021-04198-4.
Figures

Figure 1
Protocol of the study.

Figure 2
Detection of anti-SARS-CoV-2-S1 RBD-specific antibodies (% of all participants) in the period before the pandemic and during the pandemic from 2011 to 2021.

Figure 3
Detection of anti-SARS-CoV-2-S1 RBD-specific antibodies (% of all participants) in the pandemic period from 2019 to 2021.
Figure 4

Kaplan-Meier analysis for Covid-19 relapse outcome in various groups of respondents: A, vaccinated; B, IgG-positive; C, not vaccinated; D, IgG-negative.